Cultivating Cannabinoid Safety Data In US: Principles, Projects And Problems
Executive Summary
FDA offers guiding principles for research on cannabinoids’ use in food, supplements and lotions and other personal care products. It also identifies challenges to studies that generate robust data about use of the ingredients.
You may also be interested in...
US Cardiac Arrhythmia Case Could Stoke International CBD Safety Worries
A patient admitted to a US emergency department after experiencing dizziness and fainting without warning is found to have been using a cocktail of herbal dietary supplements, including CBD and CBG. The case could fuel international worries about CBD's safety, for example in the EU, where novel food applications were recently put on hold by EFSA because of safety data gaps.
EU CBD Novel Food Applications On Hold As EFSA Considers Health Risks
All European Union CBD novel food applications have been paused by EFSA after its Panel on Nutrition, Novel Foods and Food Allergens raised concerns about the ingredient's safety, pointing in a wide-ranging scientific literature review to a number of data gaps related to bioavailability, liver damage, gastrointestinal issues and possible negative impacts on pregnancy and reproductive health.
House Appropriators Sound Off During FDA Hearing About Formula, More Consumer Health Issues
Before Agriculture/FDA subcommittee about FY2023 budget, Commissioner Robert Califf says FDA needs more resources to address unlisted fragrances in menstrual products and doesn’t have good regulatory options for hemp and kratom. His formula emergency comments leave members frustrated.